Viatris aktuell WKN: A2QAME ISIN: US92556V1061 Kürzel: VTRS Forum: Aktien User: DonauPirat

YoY (adjusted) Revenues down 1% (ex FX) Gross profit down 6% EBITDA down 3%

GAAP EPS of $0.33 beats by $0.25, revenue of $4.19B misses by $70M

EBITDA Beats Consensus // Even as Revenue Falls Short

PITTSBURGH , May 9, 2022 /PRNewswire/ -- First-Quarter 2022 Results Reflect Strong Operational Start to the Year Total Revenues Were $4.19 billion U.S. GAAP Net Earnings Were $399.2 million Adjusted EBITDA was $1.59 billion U.S. GAAP Net Cash Provided by Operating Activities was $1.14 billion Free Cash Flow was $1.07 billion Achieves Approximately $120 million in New Product Revenue, on Track for 2022 Target of $600 million Confirms Biocon Biologics Transaction on Track for Second Half 2022 Close Announces Board of Directors Declares Quarterly Dividend of Twelve Cents ($0.12) per Share Pays Down Approximately $840 million of Debt, on Track for 2022 Target of Approximately $2 billion, and Maintains Commitment to Investment Grade Rating

---- Gleich kommen die Earnings Q1 ----

Kapitalerhöhung bzw neue Schulden?!

Was sind diese SEC Fillings?

9,43€

9.25€

9,27€

-3%

9,28€

-2%

9,32€

-1%

9,39€